New biotech Exalys, seek­ing to pre­vent post­op­er­a­tive delir­i­um, launch­es with $15 mil­lion in Se­ries A

An old group of for­mer col­leagues will be re­unit­ing to lead a new biotech ven­ture aimed at cul­ti­vat­ing a port­fo­lio to treat neu­roin­flam­ma­to­ry dis­or­ders.

Led by Rick Orr, who ran the biotech Ad­ynxx, the group is launch­ing the start­up Exalys on Thurs­day with $15 mil­lion in Se­ries A fund­ing from ven­ture firms Catalys Pa­cif­ic and Do­main As­so­ciates. The nascent com­pa­ny’s first project will fo­cus on pre­vent­ing post­op­er­a­tive delir­i­um, li­cens­ing a plat­form of EP4 re­cep­tors from Japan­ese phar­ma Ei­sai.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.